Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2014

View Archived Issues

Stallergenes and ActoGenix to develop new class of oral allergy treatments

FUJIFILM Pharma signs an agreement with Merck Serono for Saizen

Yabao Pharmaceutical and MRC Technology collaborate to discover Parkinson's disease drugs

In vivo data presented for the selective LSD1 inhibitor GSK-2879552

Novel gene linked to mitochondrial myopathy

Protective effect of a vaccine against cutaneous leishmaniasis in a canine model

Merck KGaA patents new GCN2 inhibitors

U.S. investigators disclose new class II FBA inhibitors

Rociletinib shows good tolerability and durable activity in the phase I/II TIGER-X study

CRT teams up with Cancer Research UK Manchester to develop lung cancer drugs

Intra-Cellular Therapies reports additional data from phase I/II trial of ITI-007

PRO-028 and PRO-027: novel NAC analogues for cocaine addiction

Modified human cardiac stem cells overexpressing SDF-1-alpha enhance cardiac repair

Novel TGF-beta inhibitors disclosed by U.S. institutions

Brown University divulges novel selective bacterial proteasome inhibitors

Nimbus Apollo discloses new ACC2 inhibitors

University of Florida presents novel peptidomimetic antimicrobials

Santen launches TAPCOM solution for glaucoma and ocular hypertension

FDA approves Onexton gel for the treatment of acne vulgaris

ATX-F8-117 receives European orphan medicinal product designation for hemophilia A

First-in-human study of OBT-357 begins in acute myeloid leukemia

Soliris receives orphan drug designation in Japan for neuromyelitis optica

Ipsen and collaborators establish Archi-Pex joint research and innovation lab

Ocata granted European ATMP designation for RPE program for macular degeneration

Calzada to divest interest in Metabolic Pharmaceuticals

BioMarin Pharmaceutical to acquire Prosensa

Corporate name changes for Bioniche Life Sciences and Aastrom Biosciences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...